Vimarsana
Biggest News Aggregation in the World

Page 37 - Group Information News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Group Information. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Group Information Today - Breaking & Trending Today

Global MNO Directory 2023-2024: Connect with Key Decision-Makers and Unlock Worldwide Business Opportunities - Vimarsana News

Global MNO Directory 2023-2024: Connect with Key Decision-Makers and Unlock Worldwide Business Opportunities

/PRNewswire/ -- The "Worldwide MNO Directory 2023-2024" directory has been added to ResearchAndMarkets.com's offering. This directory will help telecom service...

Continuous vs Intermittent Meropenem Administration in Critically Ill Patients With Sepsis - Vimarsana News

Continuous vs Intermittent Meropenem Administration in Critically Ill Patients With Sepsis

This randomized clinical trial compares the effect of continuous administration of meropenem vs intermittent administration on a composite outcome of mortality

Worldwide MNO-MVNO (Mobile Network Operators/Mobile Virtual Network Operators) Directory 2023: CXO/Management/Decision-Makers/Influencer contacts - Vimarsana News

Worldwide MNO-MVNO (Mobile Network Operators/Mobile Virtual Network Operators) Directory 2023: CXO/Management/Decision-Makers/Influencer contacts

/PRNewswire/ -- The "Worldwide MNO-MVNO (Mobile Network Operators - Mobile Virtual Network Operators) 2023-2024 (Special Combo Edition)" report has been added...

Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial | JAMA - Vimarsana News

Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial | JAMA

This randomized trial assesses the comparative effectiveness of direct oral anticoagulants vs low-molecular-weight heparin on rate of 6-month recurrence of veno

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial | Infectious Diseases | JAMA - Vimarsana News

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial | Infectious Diseases | JAMA

This open-label randomized trial compares the effect of remdesivir (5 or 10 days) vs standard care on clinical status 11 days after treatment initiation among p